Ligand Pharmaceuticals, Inc. - Class B

LGND

$74.28

-17.2% last 12 months

Ken Griffin Holding value: $5.41 Million Ken Fisher Holding value: $2.98 Million Jim Simons Holding value: $2.21 Million Joel Greenblatt Holding value: $315 Thousand Steven Cohen Holding value: $6.02 Thousand Mario Gabelli Holding value: $0 Daniel Loeb Holding value: $0 George Soros Holding value: $0

Market Cap

$1.23 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$60.12 - $109.00

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

51.3x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $1.23 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $1.02 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield. -17.2%
52-Week High Highest share price in the last 52 weeks. $109.00
52-Week Low Lowest share price in the last 52 weeks. $60.12
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.0
Outstanding Shares The number of shares the company has issued and are held by stockholders. 17.3 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 96 Thousand

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 51.3
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. -13.77
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $1.40
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 6.75
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 2.01
Enterprise Value to Revenue Enterprise value divided by revenue 5.26
Enterprise Value to EBIT Enterprise Value divided by EBIT 12.97
Total Debt to Enterprise Value Total debt divided by enterprise value 0.08
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.12

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $195 Million
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $143 Million
EBIT Earnings before tax and interest payments. $79 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $24 Million
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 12.32%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -372.7%
Return on Equity Equity divided by market cap. 3.71%
Return on Assets Indicates a company's profitability in relation to its total assets. 2.96%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 11.09%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q3 2022 Q4 2022 Q1 2023 Q2 2023

About Ligand Pharmaceuticals, Inc. - Class B

CEO: John Higgins

Industry: Pharmaceutical Preparation Manufacturing

Similar stocks

AMGEN Inc.
AMGEN Inc.
Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc.
GSK Plc - ADR
GSK Plc - ADR
Merck & Co Inc
Merck & Co Inc
Pfizer Inc.
Pfizer Inc.
Lilly(Eli) & Co
Lilly(Eli) & Co
Baxter International Inc.
Baxter International Inc.
Johnson & Johnson
Johnson & Johnson

News

Ligand Pharmaceuticals (NASDAQ:LGND) PT Raised to $144.00

Ligand Pharmaceuticals (NASDAQ:LGND) PT Raised to $144.00

Ligand Pharmaceuticals (NASDAQ:LGND – Get Rating) had its target price boosted by research analysts at HC Wainwright from $135.00 to $144.00 in a note issued...

The AM Reporter The AM Reporter, 5 days ago
3 Stocks That Smart Investors Should Be Flocking to Now

3 Stocks That Smart Investors Should Be Flocking to Now

Although investors can bag profits by following the masses, it’s also possible to accrue substantive rewards by walking the path least traveled with top stoc...

InvestorPlace InvestorPlace, 10 days ago
Director of Ligand Pharmaceuticals Makes $343K Sale

Director of Ligand Pharmaceuticals Makes $343K Sale

John W Kozarich , Director at Ligand Pharmaceuticals (NASDAQ: LGND ), reported a large insider sell on May 18, according to a new SEC filing. What Happened: ...

Benzinga Benzinga, 21 days ago
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial

Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial

Ligand Pharmaceuticals Incorporated''s (NASDAQ: LGND ) partner Viking Therapeutics Inc (NASDAQ: VKTX ) announced positive topline results from its Phase 2b t...

Benzinga Benzinga, 24 days ago
Never miss a trade
To improve your user experience we use cookies.